Trial · NCT07897968
GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
NCT07897968, Phase 1, Not yet recruiting, Universität Münster
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors. Trials, record NCT07897968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors
- NCT number
- NCT07897968
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Universität Münster
- Conditions
- Neuroblastoma (NBL), Ewing Sarcoma, Osteosarcoma
- Interventions
- Chimeric Antigen Receptor (CAR) Therapy Infusion, Bevacizumab (Avastin)
- First posted
- 2026-10-27
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of adverse events | Through 12 months after GD2IL18CART infusion | Incidence and severity of adverse events (AEs), graded according to CTCAE version 6.0 |
| Primary | Dose-limiting toxicities and recommended dose - dose-finding part | 28 days after IMP infusion | Incidence of protocol-defined dose-limiting toxicities (DLTs) and determination of the recommended dose (RD) of GD2IL18CART in combination with bevacizumab using a rule-based small-cohort design |
| Primary | Recommended dose of GD2IL18CART in combination with bevacizumab | Through completion of the protocol-defined DLT assessment period of 28 days for the final dose-finding cohort | Determination of the recommended dose (RD) of GD2IL18CART in combination with bevacizumab using a rule-based small-cohort dose-escalation design, based on observed dose-limiting toxicities (DLTs) and protocol-defined dose-escalation and stopping rules. |
| Primary | Overall response rate at week 6 - dose-extension part | Week 6 | Proportion of participants achieving a complete response (CR) or partial response (PR) at week 6 |
| Secondary | Intratumoral infiltration of GD2IL18CART | Day 14 | Presence and extent of GD2IL18CART-cell infiltration in on-treatment tumor biopsies |
| Secondary | Expansion and persistence of GD2IL18CART | From GD2IL18CART infusion through 12 months | Longitudinal assessment of GD2IL18CART-cell expansion, persistence and phenotype in peripheral blood |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38593230 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897968
GET https://conductscience.org/api/trials/v1/NCT07897968/registered